BRCA in breast cancer: ESMO Clinical Recommendations

Annals of Oncology

Volumn 20, Issue SUPPL. 4, 2009, Pages

  Balmana J ^a   Diez O ^a   Castiglione, M ^b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER PALLIATIVE THERAPY; CLINICAL PROTOCOL; FAMILIAL CANCER; GENE MUTATION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HUMAN; MAMMOGRAPHY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK REDUCTION; SALPINGOOOPHORECTOMY;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; EUROPE; FEMALE; GENETIC TESTING; HEALTH PLANNING GUIDELINES; HUMANS; MUTATION; PREVALENCE; PROTEIN-SERINE-THREONINE KINASES; PTEN PHOSPHOHYDROLASE; SOCIETIES, MEDICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 66549093575     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp116     Document Type: Article

References (9)

1. Fackental JD, Olopade OI. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 2007; 7: 937-948.
2. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676-689.
3. Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-1130.
4. Walsh T, Casadei S, Coats KH et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006; 295: 1379-1388.
5. Kriege M, Brekelmans CT, Boetes C et al. Efficacy of MRI and mammography for breast cancer screening in women with familial or genetic predisposition. N Engl J Med 2004; 351: 427-437.
6. Gronwald J, Tung N, Foulkes WD et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update. Int J Cancer 2006; 118: 2281-2284.
7. Meijers-Heijboer H, van Geel B, van Putten WL et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345: 159-164.
8. Domcheck SM, Friebel TM, Neuhausen SL et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 2006; 7: 223-229.
9. Domcheck SM, Weber BL. Clinical management of BRCA1 and BRCA2 mutation carriers. Oncogene 2006; 25: 5825-5831.